Alfredo Addeo
Alfredo Addeo
Oncology department , University Hospital of Geneva
Verified email at
Cited by
Cited by
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
G Curigliano, S Banerjee, A Cervantes, MC Garassino, P Garrido, ...
Annals of Oncology 31 (10), 1320-1335, 2020
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer
A Addeo, PK Shah, N Bordry, RD Hudson, B Albracht, M Di Marco, ...
Cancer cell 39 (8), 1091-1098. e2, 2021
ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer
A Passaro, A Addeo, C Von Garnier, F Blackhall, D Planchard, E Felip, ...
ESMO open 5, e000820, 2020
Cancer and COVID-19: Unmasking their ties
A Addeo, A Friedlaender
Cancer treatment reviews 88, 102041, 2020
How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere
G Banna, A Curioni-Fontecedro, A Friedlaender, A Addeo
ESMO open 4, e000765, 2019
TMB or not TMB as a biomarker: That is the question
A Addeo, A Friedlaender, GL Banna, GJ Weiss
Critical Reviews in Oncology/Hematology 163, 103374, 2021
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
A Friedlaender, V Subbiah, A Russo, GL Banna, U Malapelle, C Rolfo, ...
Nature reviews Clinical oncology 19 (1), 51-69, 2022
Tumor mutation burden—from hopes to doubts
A Addeo, GL Banna, GJ Weiss
JAMA oncology 5 (7), 934-935, 2019
Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and …
A Addeo, GL Banna, G Metro, M Di Maio
Frontiers in oncology 9, 264, 2019
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
A Friedlaender, A Drilon, GJ Weiss, GL Banna, A Addeo
Cancer treatment reviews 85, 101978, 2020
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
M Chevallier, M Borgeaud, A Addeo, A Friedlaender
World Journal of Clinical Oncology 12 (4), 217, 2021
New emerging targets in cancer immunotherapy: the role of TIM3
A Friedlaender, A Addeo, G Banna
ESMO open 4, e000497, 2019
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab …
A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ...
Journal for immunotherapy of cancer 9 (4), 2021
COVID-19 and lung cancer: risks, mechanisms and treatment interactions
A Addeo, M Obeid, A Friedlaender
Journal for immunotherapy of cancer 8 (1), 2020
Next generation sequencing and genetic alterations in squamous cell lung carcinoma: where are we today?
A Friedlaender, G Banna, U Malapelle, P Pisapia, A Addeo
Frontiers in oncology 9, 166, 2019
The FDA approval of pembrolizumab for patients with TMB> 10 mut/Mb: was it a wise decision? No
V Prasad, A Addeo
Annals of Oncology 31 (9), 1112-1114, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50%
A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ...
Cancer Immunology, Immunotherapy 69, 2209-2221, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation
A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ...
Journal for immunotherapy of cancer 8 (2), 2020
Immunotherapy in non-small cell lung cancer harbouring driver mutations
A Addeo, A Passaro, U Malapelle, GL Banna, V Subbiah, A Friedlaender
Cancer treatment reviews 96, 2021
Targeted therapies in early stage NSCLC: hype or hope?
A Friedlaender, A Addeo, A Russo, V Gregorc, D Cortinovis, CD Rolfo
International journal of molecular sciences 21 (17), 6329, 2020
The system can't perform the operation now. Try again later.
Articles 1–20